Krystal Biotech Inc.(KRYS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KRYS Krystal Biotech Inc.

盘前交易 05-19 08:09:31 EDT

291.75

-14.54

-4.75%

盘前293.11

+1.36+0.47%

08:05 EDT

最高308.99	最低289.39	成交量29.92万
今开308.00	昨收306.29	日振幅6.40%
总市值85.88亿	流通市值67.04亿	总股本2,944万
成交额8,820万	换手率1.30%	流通股本2,298万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KRYS","market":"US","secType":"STK","nameCN":"Krystal Biotech Inc.","latestPrice":291.75,"timestamp":1779134400000,"preClose":306.29,"halted":0,"volume":299207,"hourTrading":{"tag":"盘前","latestPrice":293.11,"preClose":291.75,"latestTime":"08:05 EDT","volume":11,"amount":3225.10375,"timestamp":1779192331783,"change":1.36,"changeRate":0.004662,"amplitude":0.003256},"delay":0,"changeRate":-0.04747135068072748,"floatShares":22979893,"shares":29435746,"eps":7.47,"marketStatus":"盘前交易","change":-14.54,"latestTime":"05-19 08:09:31 EDT","open":308,"high":308.99,"low":289.39,"amount":88195099.08374,"amplitude":0.063992,"askPrice":309.99,"askSize":8,"bidPrice":289.51,"bidSize":7,"shortable":3,"etf":0,"ttmEps":7.47,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779197400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":291.75,"preHourTrading":{"tag":"盘前","latestPrice":293.11,"preClose":291.75,"latestTime":"08:05 EDT","volume":11,"amount":3225.10375,"timestamp":1779192331783,"change":1.36,"changeRate":0.004662,"amplitude":0.003256},"postHourTrading":{"tag":"盘后","latestPrice":288.5,"preClose":291.75,"latestTime":"19:55 EDT","volume":4157,"amount":1212240.6901,"timestamp":1779148547198,"change":-3.25,"changeRate":-0.01114,"amplitude":0.012853},"volumeRatio":0.8662136716031777,"impliedVol":0.087,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/KRYS","defaultTab":"news","newsList":[{"id":"1141970680","title":"Krystal Biotech宣布Vyjuvek®获英国MHRA批准用于治疗营养不良型大疱性表皮松解症","url":"https://stock-news.laohu8.com/highlight/detail?id=1141970680","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141970680?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:00","pubTimestamp":1779105630,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.  宣布，其基因疗法Vyjuvek已获得英国药品和保健品监管局的批准，适用于治疗营养不良型大疱性表皮松解症患者。英国监管机构的批准，是基于其先前在美国获得FDA批准以及一系列临床试验所展示出的积极疗效与安全性数据。此次获批有望进一步拓宽Krystal Biotech的市场覆盖，并强化其在基因治疗领域的地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154454876","title":"英国MHRA批准Beremagene Geperpavec（Vyjuvek）用于治疗营养不良型大疱性表皮松解症","url":"https://stock-news.laohu8.com/highlight/detail?id=1154454876","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154454876?lang=zh_cn&edition=full","pubTime":"2026-05-16 02:12","pubTimestamp":1778868734,"startTime":"0","endTime":"0","summary":"英国药品和健康产品管理局（MHRA）已正式批准基因疗法Beremagene Geperpavec（商品名Vyjuvek）用于治疗营养不良型大疱性表皮松解症。这一决定为患有此种罕见且严重遗传性皮肤病的患者提供了一种新的治疗选择。\n该疗法由Krystal Biotech Inc.研发，旨在通过局部应用纠正导致皮肤脆弱和水疱形成的基因缺陷。此次批准标志着英国在推进创新基因疗法以应对未满足的医疗需求方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168363780","title":"财报前瞻｜Krystal Biotech Inc.本季度营收预计增16.30%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1168363780","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168363780?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:06","pubTimestamp":1777251990,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.将于2026年05月04日发布财报，市场关注Vyjuvek商业放量与利润率走势。综合一致预期显示，本季度Krystal Biotech Inc.营收预计为1.12亿美元，同比增16.30%；调整后每股收益预计为1.39美元，同比增1.92%；息税前利润预计为4,583.62万美元，同比增26.75%。上季度Krystal Biotech Inc.营收为1.07亿美元，同比增长17.52%；毛利率为93.85%；归属于母公司股东的净利润为5,140.00万美元，净利率为47.99%；调整后每股收益为1.70美元，同比增长11.84%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Krystal Biotech Inc.本季度营收预计增16.30%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129093196","title":"Palvella Therapeutics任命罕见病商业领袖Jennifer J. Mcdonough为市场准入与患者服务高级副总裁，强化领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1129093196","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129093196?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:35","pubTimestamp":1774265729,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布了一项重要人事任命，罕见病领域的商业领袖Jennifer J. Mcdonough已加入公司，担任市场准入与患者服务高级副总裁。这一举措旨在加强公司的领导团队实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100033579","title":"Krystal Biotech宣布FDA授予KB707再生医学先进疗法认定，用于治疗晚期或转移性非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1100033579","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100033579?lang=zh_cn&edition=full","pubTime":"2026-02-09 21:03","pubTimestamp":1770642196,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.宣布，其候选疗法KB707已获得美国食品药品监督管理局（FDA）授予的再生医学先进疗法（RMAT）认定，适应症为晚期或转移性非小细胞肺癌（NSCLC）。\nRMAT认定旨在加速针对严重或危及生命疾病的新型再生医学产品的开发和审评。此次认定基于KB707在临床前研究中展现出的潜力，该疗法是一种基于基因工程的创新疗法。\n获得RMAT资格意味着KB707有资格获得FDA的强化指导，并可能获得优先审评和加速批准等便利。这对于推进该疗法的临床开发进程具有重要意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110133427","title":"Krystal Biotech公布KB407一期Coral-1研究积极中期临床数据，证实野生型CFTR成功递送至囊性纤维化患者肺部","url":"https://stock-news.laohu8.com/highlight/detail?id=1110133427","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110133427?lang=zh_cn&edition=full","pubTime":"2026-01-09 05:03","pubTimestamp":1767906219,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.宣布，其KB407在一期临床试验Coral-1研究中取得积极的中期临床进展。该研究成功证实，能够将野生型CFTR递送至囊性纤维化患者的肺部。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177006781","title":"Krystal Biotech Inc. 报告支气管镜检查完成后24小时出现哮喘加重严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1177006781","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177006781?lang=zh_cn&edition=full","pubTime":"2026-01-09 05:03","pubTimestamp":1767906200,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc. 披露，一名患者在完成支气管镜检查24小时后，报告出现了哮喘加重的严重不良事件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131298760","title":"Krystal Biotech将公布KB407治疗囊性纤维化患者1期Coral-1研究最高剂量组中期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1131298760","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131298760?lang=zh_cn&edition=full","pubTime":"2026-01-08 05:06","pubTimestamp":1767819980,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc. (KRYS) 即将发布其1期Coral-1临床试验的最新进展。此次更新重点关注最高剂量组的中期结果，该研究旨在评估基因疗法KB407对囊性纤维化患者的疗效与安全性。\n这一关键数据的披露，将为投资者和医学界提供重要参考，揭示KB407在更高剂量水平下的潜在治疗价值。公司此举标志着其在呼吸系统疾病基因治疗领域又迈出坚实一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124751947","title":"Krystal Biotech 第三季度净收入为7936.5万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124751947","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124751947?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:27","pubTimestamp":1763569640,"startTime":"0","endTime":"0","summary":"11月3日 - Krystal Biotech 第三季度产品收入为9780万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513752603","title":"Krystal Biotech, Inc.2024财年实现净利润89.16百万美元，同比增加715.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513752603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513752603?lang=zh_cn&edition=full","pubTime":"2025-02-24 03:00","pubTimestamp":1740337251,"startTime":"0","endTime":"0","summary":"2月24日，Krystal Biotech, Inc.公布财报，公告显示公司2024财年净利润为89.16百万美元，同比增加715.74%；其中营业收入为2.91亿美元，同比增加473.96%，每股基本收益为3.12美元。从资产负债表来看，Krystal Biotech, Inc.总负债1.09亿美元，其中短期债务1.22百万美元，资产负债比为9.69，流动比率为7.28。机构评级：截至2025年2月24日，当前有9家机构对Krystal Biotech, Inc.目标价做出预测，其中目标均价为211.44美元，其中最低目标价为195.00美元，最高目标价为221.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224030058abd9e675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224030058abd9e675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157840734","title":"异动解读 | 基因疗法公司研发利好 Krystal Biotech Inc.盘中大涨5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157840734","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157840734?lang=zh_cn&edition=full","pubTime":"2025-02-20 23:00","pubTimestamp":1740063626,"startTime":"0","endTime":"0","summary":"生物科技公司Krystal Biotech Inc.(KRYS)今日盘中大涨5.61%,引发市场广泛关注。\n\n据分析,这主要得益于分析师机构Chardan Capital发布研究报告,维持该公司股票评级为\"买入\",并将目标价从212美元上调至218美元。分析师对该公司前景持乐观态度。\n\nKrystal Biotech Inc.是一家专注于开发新型生物疫苗和基因疗法的临床阶段公司。公司最近在研发方面取得了一定进展,这增强了市场对其长期增长潜力的信心,成为分析师上调评级目标价的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124658988","title":"异动解读 | Krystal Biotech Inc.(KRYS)盘前大涨5.02%，分析师上调评级目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1124658988","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124658988?lang=zh_cn&edition=full","pubTime":"2025-02-20 22:28","pubTimestamp":1740061707,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.(KRYS)今日盘前大涨5.02%,引发市场关注。\n\n分析师机构Chardan Capital发布研报,维持该公司股票评级为\"买入\",同时将目标价从212美元上调至218美元。分析师对该公司前景持乐观态度。\n\nKrystal Biotech是一家临床阶段的基因疗法公司,专注于开发新型生物疫苗。公司最近取得了一些研发进展,这可能是分析师上调评级目标价的主要原因。总体来说,市场对该公司长期增长潜力充满信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Krystal Biotech Inc.(KRYS)盘前大涨5.02%，分析师上调评级目标价","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512448404","title":"Chardan Capital：维持Krystal Biotech(KRYS.US)评级，由买入调整至买入评级, 目标价由212.00美元调整至218.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512448404","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512448404?lang=zh_cn&edition=full","pubTime":"2025-02-20 19:10","pubTimestamp":1740049835,"startTime":"0","endTime":"0","summary":"Chardan Capital：维持Krystal Biotech(KRYS.US)评级，由买入调整至买入评级, 目标价由212.00美元调整至218.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/20191048285027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178376665","title":"异动解读 | Krystal Biotech财报超预期 股价暴涨5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178376665","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178376665?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:39","pubTimestamp":1739975979,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.(纳斯达克代码:KRYS)盘中股价大涨5.85%,引起了资本市场的关注。\n\n导致该股暴涨的主因是Krystal Biotech公布了2024年第四季度财报,实现了业绩超预期。\n\n具体来看,Krystal Biotech2024年第四季度实现每股收益1.52美元,较去年同期快速增长406.67%,并高于分析师普遍预期31.03%。销售额达到91.14百万美元,同比增长116.26%,超出分析师预期0.72%。公司业绩显著增长,销售额和利润率均超过市场预期,让投资者对公司长期发展前景更加看好,从而推动了当日股价大涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512838754","title":"Krystal Biotech, Inc.盘中异动 早盘大幅下跌5.28%报148.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512838754","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512838754?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:31","pubTimestamp":1739975469,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时31分，Krystal Biotech, Inc.股票出现波动，股价快速下跌5.28%。截至发稿，该股报148.42美元/股，成交量9687股，换手率0.03%，振幅0.41%。Krystal Biotech, Inc.股票所在的生物技术行业中，整体跌幅为0.15%。其相关个股中，Osr Holdings, Inc.、Aditxt, Inc.、Citius Pharmaceuticals, Inc.涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Chemomab Therapeutics Ltd较为活跃，换手率分别为202.08%、200.84%、65.46%，振幅较大的相关个股有Azitra Inc、Cellectar Biosciences, Inc.、Glycomimetics, Inc.，振幅分别为11.29%、6.05%、5.46%。Krystal Biotech, Inc.公司简介：Krystal Biotech Inc在美国从事医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502192231109628cd1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502192231109628cd1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141400298","title":"Krystal Biotech 2024年第四季度GAAP每股收益$1.52, 超过预期$1.16，销售额$91.14M, 超过预期$90.49M","url":"https://stock-news.laohu8.com/highlight/detail?id=1141400298","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141400298?lang=zh_cn&edition=full","pubTime":"2025-02-19 20:07","pubTimestamp":1739966856,"startTime":"0","endTime":"0","summary":"Krystal Biotech报告季度每股收益为$1.52，这超过了分析师普遍预计的$1.16，超出31.03%。该公司报告季度销售额为$91.14百万，超过了分析师普遍预计的$90.49百万，超出0.72%。这与去年同期销售额$42.14百万相比增长了116.26%。以上内容来自Benzinga Earnings专栏，原文如下：Krystal Biotech  reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.16 by 31.03 percent. This is a 406.67 percent increase over earnings of $0.30 per share from the same period last year.  The company reported quarterly sales of $91.14 million which beat the analyst consensus estimate of $","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Krystal Biotech 2024年第四季度GAAP每股收益$1.52, 超过预期$1.16，销售额$91.14M, 超过预期$90.49M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503686542","title":"Krystal Biotech, Inc.盘中异动 股价大跌5.29%报142.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503686542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503686542?lang=zh_cn&edition=full","pubTime":"2025-01-15 04:05","pubTimestamp":1736885147,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日04时05分，Krystal Biotech, Inc.股票出现异动，股价急速跳水5.29%。截至发稿，该股报142.37美元/股，成交量19.9784万股，换手率0.69%，振幅6.69%。Krystal Biotech, Inc.股票所在的生物技术行业中，整体跌幅为1.27%。其相关个股中，Eterna Therapeutics Inc.、Jasper Therapeutics Inc C/Wts 24/09/2026 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 涨幅较大，Eterna Therapeutics Inc.、Phio Pharmaceuticals Corp.、Soligenix, Inc.较为活跃，换手率分别为1082.51%、603.06%、421.58%，振幅较大的相关个股有Eterna Therapeutics Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Matinas Biopharma Holdings, Inc.，振幅分别为170.74%、146.24%、69.81%。Krystal Biotech, Inc.公司简介：Krystal Biotech Inc在美国从事医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115040547a221fdfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115040547a221fdfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492315376","title":"Krystal Biotech, Inc.盘中异动 下午盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492315376","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492315376?lang=zh_cn&edition=full","pubTime":"2024-12-19 04:00","pubTimestamp":1734552021,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日04时00分，Krystal Biotech, Inc.股票出现波动，股价急速下挫5.06%。截至发稿，该股报160.50美元/股，成交量15.6757万股，换手率0.55%，振幅9.31%。Krystal Biotech, Inc.股票所在的生物技术行业中，整体跌幅为1.89%。其相关个股中，Polyrizon Ltd.、Tc Biopharm  Plc C/Wts 10/02/2028 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com涨幅较大，Polyrizon Ltd.、Cognition Therapeutics, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为3176.65%、663.05%、346.50%，振幅较大的相关个股有Polyrizon Ltd.、Cognition Therapeutics, Inc.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025，振幅分别为227.62%、138.10%、105.17%。Krystal Biotech, Inc.公司简介：Krystal Biotech Inc在美国从事医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219040021ab828e0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219040021ab828e0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492858610","title":"Krystal Biotech, Inc.盘中异动 股价大涨5.41%报172.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492858610","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492858610?lang=zh_cn&edition=full","pubTime":"2024-12-17 01:46","pubTimestamp":1734371167,"startTime":"0","endTime":"0","summary":"北京时间2024年12月17日01时46分，Krystal Biotech, Inc.股票出现异动，股价急速拉升5.41%。截至发稿，该股报172.50美元/股，成交量10.2298万股，换手率0.36%，振幅5.48%。Krystal Biotech, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。Krystal Biotech, Inc.公司简介：Krystal Biotech Inc在美国从事医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217014607ab7ce9a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217014607ab7ce9a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2491339695","title":"Krystal Biotech, Inc.盘中异动 快速跳水5.41%报177.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491339695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491339695?lang=zh_cn&edition=full","pubTime":"2024-12-13 00:45","pubTimestamp":1734021930,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日00时45分，Krystal Biotech, Inc.股票出现异动，股价大幅下挫5.41%。截至发稿，该股报177.00美元/股，成交量14.0562万股，换手率0.49%，振幅8.10%。Krystal Biotech, Inc.股票所在的生物技术行业中，整体跌幅为0.95%。Krystal Biotech, Inc.公司简介：Krystal Biotech Inc在美国从事医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213004530984b9bdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213004530984b9bdd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.krystalbio.com","stockEarnings":[{"period":"1week","weight":-0.0675},{"period":"1month","weight":0.064},{"period":"3month","weight":0.0136},{"period":"6month","weight":0.4294},{"period":"1year","weight":1.2339},{"period":"ytd","weight":0.1834}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Krystal Biotech, Inc.于2016年4月开始运营。2017年3月，他们从加利福尼亚州有限责任公司转换为特拉华州C-corporation，并将其名称从Krystal Biotech, LLC更改为Krystal Biotech, Inc。该公司是一家专注于为罕见病患者开发和商业化基因药物的生物技术公司。利用他们基于工程化HSV-1的专利平台，他们创造了载体，可以有效地将治疗性转基因传递给多器官系统中感兴趣的细胞。然后，细胞自身的机制转录并翻译编码的效应物来治疗或预防疾病。他们在医疗保健专业人员的办公室或可能由医疗保健专业人员在患者家中制定无创或微创给药途径的载体。他们的目标是开发易于使用的药物，以显著改善患有罕见疾病和慢性疾病的患者的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.012037},{"month":2,"riseRate":0.666667,"avgChangeRate":0.08189},{"month":3,"riseRate":0.555556,"avgChangeRate":0.037905},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.016835},{"month":5,"riseRate":0.555556,"avgChangeRate":0.023825},{"month":6,"riseRate":0.75,"avgChangeRate":0.115596},{"month":7,"riseRate":0.75,"avgChangeRate":0.07679},{"month":8,"riseRate":0.125,"avgChangeRate":-0.010983},{"month":9,"riseRate":0.25,"avgChangeRate":-0.037914},{"month":10,"riseRate":0.555556,"avgChangeRate":0.053086},{"month":11,"riseRate":0.888889,"avgChangeRate":0.190014},{"month":12,"riseRate":0.555556,"avgChangeRate":-0.011676}],"exchange":"NASDAQ","name":"Krystal Biotech Inc.","nameEN":"Krystal Biotech Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Krystal Biotech Inc.(KRYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Krystal Biotech Inc.(KRYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Krystal Biotech Inc.,KRYS,Krystal Biotech Inc.股票,Krystal Biotech Inc.股票老虎,Krystal Biotech Inc.股票老虎国际,Krystal Biotech Inc.行情,Krystal Biotech Inc.股票行情,Krystal Biotech Inc.股价,Krystal Biotech Inc.股市,Krystal Biotech Inc.股票价格,Krystal Biotech Inc.股票交易,Krystal Biotech Inc.股票购买,Krystal Biotech Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Krystal Biotech Inc.(KRYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Krystal Biotech Inc.(KRYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}